An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival

Carcinogenesis

Volumn 34, Issue 9, 2013, Pages 2024-2030

  Lu, Lingeng ^a,b   Risch, Evan ^a   Deng, Qian ^a,c   Biglia, Nicoletta ^d   Picardo, Elisa ^e   Katsaros, Dionyssios ^e   Yu, Herbert ^a,b,f  

^a YALE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d MAURIZIANO HOSPITAL   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GENOMIC DNA; SOMATOMEDIN B;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CIRCULAR DICHROISM; CONTROLLED STUDY; DNA CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVARY CARCINOMA; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR INVASION;

BIOMARKERS, PHARMACOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INTRONS; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; NUCLEIC ACID CONFORMATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84887013287     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt168     Document Type: Article

References (39)

1. Toretsky, J.A. et al. (1996) Involvement of IGF-II in human cancer. J. Endocrinol., 149, 367-372.
2. Lu, L. et al. (2006) Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol. Oncol., 103, 990-995.
3. Freier, S. et al. (1999) Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut, 44, 704-708.
4. Li, S.L. et al. (1998) Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res., 291, 469-479.
5. Shiraishi, T. et al. (1998) Expression of insulin-like growth factor 2 mRNA in human gastric cancer. Int. J. Oncol., 13, 519-523.
6. van Roozendaal, C.E. et al. (1998) Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett., 437, 107-111.
7. Sawiris, G.P. et al. (2002) Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res., 62, 2923-2928.
8. Yun, K. et al. (1996) Monoallelic expression of the insulin-like growth factor-gene in ovarian cancer. Am. J. Pathol., 148, 1081-1087.
9. Sayer, R.A. et al. (2005) High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol. Oncol., 96, 355-361.
10. Lu, L. et al. (2006) The relationship of insulin-like growth factor-II, insulinlike growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin. Cancer Res., 12, 1208-1214.
11. Risch, H.A. et al. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst., 98, 1694-1706.
12. Pharoah, P.D. et al. (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet., 45, 362-370.
13. Pearce, C.L. et al. (2011) Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum. Mol. Genet., 20, 2263-2272.
14. Nikolova, E.N. et al. (2011) Transient Hoogsteen base pairs in canonical duplex DNA. Nature, 470, 498-502.
15. Kitayner, M. et al. (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat. Struct. Mol. Biol., 17, 423-429.
16. Chen, Y. et al. (2010) Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure, 18, 246-256.
17. Kypr, J. et al. (2009) Circular dichroism and conformational polymorphism of DNA. Nucleic Acids Res., 37, 1713-1725.
18. Ivanov, V.I. et al. (1974) The B to A transition of DNA in solution. J. Mol. Biol., 87, 817-833.
19. Vorlícková, M. et al. (1982) Conformational transitions of poly(dA-dT) poly(dA-dT) in ethanolic solutions. Nucleic Acids Res., 10, 6969-6979.
20. Sutherland, J.C. et al. (1981) Z-DNA: vacuum ultraviolet circular dichroism. Proc. Natl Acad. Sci. USA, 78, 4801-4804.
21. Sullivan, S.T. et al. (2001) A rare example of three abundant conformers in one retro model of the cisplatin-DNA d(GpG) intrastrand cross link. Unambiguous evidence that guanine O6 to carrier amine ligand hydrogen bonding is not important. possible effect of the Lippard base pair step adjacent to the lesion on carrier ligand hydrogen bonding in DNA adducts. J. Am. Chem. Soc., 123, 9345-9355.
22. Tsankov, D. et al. (2003) Cisplatin adducts of d(CCTCTG*G*TCTCC).d(G GAGACCAGAGG) in aqueous solution by vibrational circular dichroism spectroscopy. Biopolymers, 72, 490-499.
23. Takahara, P.M. et al. (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature, 377, 649-652.
24. Andrushchenko, V. et al. (2007) DNA oligonucleotide-cis-platin binding: Ab initio interpretation of the vibrational spectra. J. Phys. Chem. A, 111, 9714-9723.
25. Shepherd, J.H. (1989) Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol., 96, 889-892.
26. Scully, R. et al. (1999) Histological Typing of Ovarian Tumors. Springer, Berlin, NY.
27. Lu, L. et al. (2012) Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis, 33, 2119-2125.
28. Brewood, G.P. et al. (2008) A structural transition in duplex DNA induced by ethylene glycol. J. Phys. Chem. B, 112, 13367-13380.
29. Wan, X. et al. (2002) Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia, 4, 400-408.
30. Ogawa, T. et al. (2010) Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol., 267, 1599-1606.
31. Lund, P. et al. (2004) Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett., 206, 85-96.
32. Krishna, A.G. et al. (1998) Taxol-DNA interactions: fluorescence and CD studies of DNA groove binding properties of taxol. Biochim. Biophys. Acta, 1381, 104-112.
33. Malonga, H. et al. (2005) Taxol anticancer activity and DNA binding. Mini Rev. Med. Chem., 5, 307-311.
34. Ouameur, A.A. et al. (2004) Taxol interaction with DNA and RNA-stability and structure features. Candian J. Chem., 82, 1112-1118.
35. Zhao, C. et al. (2012) Contrasting enantioselective DNA preference: chiral helical macrocyclic lanthanide complex binding to DNA. Nucleic Acids Res., 40, 8186-8196.
36. Poklar, N. et al. (1996) Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc. Natl Acad. Sci. USA, 93, 7606-7611.
37. Kostrhunova, H. et al. (2000) Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates. Biochemistry, 39, 12639-12649.
38. Kim, S. et al. (2013) Probing allostery through DNA. Science, 339, 816-819.
39. Huang, R.S. et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res., 17, 5490-5500.